Sign In
Buy LRMR
$3.81
+0.0900 (+2.42%)
At Close: Jul 15, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
05:07pm, Tuesday, 14'th Jul 2026
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
07:57pm, Thursday, 09'th Jul 2026
NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advise
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
06:04pm, Tuesday, 07'th Jul 2026
NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (NASDAQ: LRMR). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMR
08:11pm, Wednesday, 01'st Jul 2026
NEW YORK, July 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Larimar Therapeutics, Inc. ("Larimar" or the "Company") (NASDAQ: LRMR). Such investors are advise
Larimar Therapeutics, Inc. (LRMR) Discusses Regulatory Progress and Long-Term Data for Nomlabofusp in Friedreich's Ataxia Transcript
BALA CYNWYD, Pa., June 29, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich's Ataxia
04:05pm, Friday, 26'th Jun 2026
BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas
Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update
07:00am, Thursday, 14'th May 2026
Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in se
BALA CYNWYD, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of “Buy” by Brokerages
02:22am, Monday, 27'th Apr 2026
Shares of Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten ratings firms that are presently covering the company, MarketB
Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
07:00am, Thursday, 19'th Mar 2026
* Pro forma cash, cash equivalents, and marketable securities of $244.5 million reflects $136.9 million of cash, cash equivalents and marketable securities as of December 31, 2025 combined with the $1
Investors Buy Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR)
02:06am, Sunday, 15'th Mar 2026
Larimar Therapeutics, Inc. (NASDAQ: LRMR - Get Free Report) was the target of some unusual options trading activity on Friday. Investors purchased 3,011 call options on the company. This represents an
2 Breakout Stocks to Buy Immediately
12:00pm, Sunday, 08'th Mar 2026
Tom Yeung here with your Sunday Digest . In 2015, I visited the observatory at One World Trade Center – the newly opened viewing deck on the Western Hemisphere's tallest building.
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?
11:30am, Friday, 06'th Mar 2026
Larimar's stock jumps 55% in a month after the FDA grants breakthrough therapy status to its FA drug nomlabofusp and backs a potential accelerated path.
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
04:05pm, Wednesday, 04'th Mar 2026
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea
